N/A N=91 Dementia With Lewy Bodies - Infinitome
Dementia With Lewy Bodies
Primary: Functional Connectivity Scores Between Pairs of Large Scale Brain Networks. — 0.164; 0.374; 0.344; 0.340 connectivity score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=43 Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies
Dementia With Lewy Bodies
Primary: Safety and Tolerability: Occurrence of Adverse Events (AEs) — 2; 2; 74; 37 events
Phase 4 N=20 "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"
Dementia With Lewy Bodies
Primary: Mean Initial Sleep Latency as Measured by the Maintenance of Wakefulness Test (MWT) — 7.0; 19.0 minutes — p=0.003
Phase 2 N=344 A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Lewy Body Dementia
Primary: Change From Baseline in the Continuity of Attention (CoA) Composite Score of the Cognitive Drug Research Computerized Cognition Battery (CDR-CCB) — 1.04; 0.15; 0.96…
Phase 2 N=269 Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study
Dementia With Lewy Bodies
Primary: Unified Parkinson's Disease Rating Scale-Part III (UPDRS-III) Change From Baseline at Week 24 — -0.55; 1.45; -1.29 units on a scale — p=0.158
Phase 3 N=142 A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase
Dementia With Lewy Bodies (DLB)
Primary: Change From Baseline in Mini-Mental State Examination (MMSE) Score — 0.6; 1.4; 2.2 Units on a scale
Phase 2 N=139 A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)
Dementia With Lewy Bodies (DLB)
Primary: Cognitive Function: Change From Baseline in Mini-mental State Examination (MMSE) Total at Week 12 Last Observation Carried Forward (LOCF) — 20.1; 19.7; 19.7; 18.2 Score…
Phase 2 N=91 Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies
Dementia With Lewy Bodies (DLB)
Primary: Composite Z-score of a Study-specific Neuropsychological Test Battery (NTB) Including Tests From Cogstate Battery, Letter Fluency Test and Category Fluency Test — 0.06…
Phase 2 N=34 A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology
Lewy Body Disease · Parkinson Disease
Primary: Percent Change From Baseline in Cerebrospinal Fluid (CSF) Cyclic Guanosine Monophosphate (cGMP) at Week 9 — 230.412; 250.434; 186.869; 362.519 Percent Change in CSF…
Phase 2 N=108 A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies
Dementia With Lewy Bodies (DLB)
Primary: Change From Baseline in Mini-mental State Examination (MMSE) Total — 20.9; 18.6; 0.3; 2 Score on a Scale
N/A N=15 Stimulation of Cingulo-opercular Alertness Network
Lewy Body Disease · Lewy Body Variant of Alzheimer Disease · Lewy Body Dementia With Behavioral Disturbance
Primary: Dementia Cognitive Fluctuations Scale — 11.75; 8.33 score on a scale — p=<0.001
Phase 2 N=130 Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
Dementia With Lewy Bodies
Primary: Number of Study Participants With at Least One Mild, Moderate, or Severe Treatment Emergent Adverse Events (TEAEs) — 42; 40; 37; 14 participants
Phase 2 N=34 Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
Dementia With Lewy Bodies · REM Sleep Behavior Disorder · Parkinson's Disease Dementia
Primary: Change in the Frequency of REM Sleep Behavior Disorders (RBD) From Baseline to the End of the Treatment Period (28 Days) Based on a Clinical Evaluator. — -1.47; -0.26…
N/A N=9 Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
Alzheimer Disease · Neurodegenerative Diseases
Primary: Alpha-synuclein Levels From Nasal Swabs
Phase 2 N=5 Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies
Diffuse Lewy Body Disease · Dementia With Lewy Bodies · Parkinson's Disease Dementia
Primary: Absolute 11C-PBR28 Binding (Total Distribution Volume Corrected for Free Fraction in Plasma) — 0.15 kBq·cm-3 / kBq·mL-1
N/A N=58 Social-LEAF Life Enhancing Activities for Caregivers
Social Connectedness
Primary: Patient Reported Outcome Measurement Information System (PROMIS )Positive Affect — -1.7; -0.3 units on a scale — p=0.57
Phase 2 N=206 Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies
Dementia With Lewy Bodies
Primary: Change From Baseline in the Montreal Cognitive Assessment (MoCA) Total Score at Week 12 of Treatment — 13.9; 13.8; -0.6; -0.4 score on a scale — p=0.6909
N/A N=5,325 Digital Detection of Dementia (D Cubed) Studies: D2
Alzheimer Disease and Related Dementias (ADRD)
Primary: 12-Month Cumulative Incidence of ADRD Diagnoses — 213; 134; 355 Number of new ADRD cases — p=0.006
N/A N=87 Learning to PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia
Lewy Body Disease · Parkinson Disease Dementia · Dementia With Lewy Bodies
Primary: Mastery Scale — 21.65; 18.91; 22.13; 19.2 units on a scale — p=0.36
Phase 4 N=13 Anti-Diabetic Medications to Fight PD and LBD
Lewy Body Dementia · Parkinson Disease
Primary: Change in Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Score — 3.0; -2.5; -2.5; 1.5 score on a scale — p=0.008
Phase 4 N=40 Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease
Parkinson's Disease
Primary: Unified Parkinson Disease Rating Scale (UPDRS). — 12; 12; 10; 10 units on a scale
Phase 4 N=47 A Study of L-DOPA for Depression and Slowing in Older Adults
Major Depressive Disorder · Dysthymia · Depression Not Otherwise Specified
Primary: Hamilton Rating Scale for Depression (24 Item) — 10.94 Units on a Scale
N/A N=87 Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.
Parkinson Disease · Parkinsonian Disorders
Primary: Demonstrate the Presence of Alpha-Synuclein Inclusions in the Skin of Parkinson's Disease and Compare With an Atypical Parkinsonism Group and With a Healthy Control…
Phase 4 N=127 Corticolimbic Degeneration and Treatment of Dementia
Dementia
Primary: Rate of Change of Hippocampal Volume Slope — -70.2418748; -88.4738591; -94.0768115; -46.9484805 mm^3/year — p=0.095
N/A N=104 Improvisational Movement for People With Memory Loss and Their Caregivers
Alzheimer's Disease (Incl Subtypes) · Dementia · Mild Cognitive Impairment
Primary: Quality of Life in Alzheimer's Disease (QOL-AD)--Participants With Dementia (PWD) — 35.42; 38.10; 35.56; 36.12 score on a scale
N/A N=148 STIM+: PET Biomarker Education & Disclosure
Mild Cognitive Impairment · Dementia; Alzheimer's Type (Etiology)
Primary: Participant Interest in PET Biomarker Disclosure — 73 Participants
N/A N=49 Cognitive Dysfunction in Parkinson's Disease
Parkinson's Disease
Primary: Change in Magnetoencephalography (MEG) Connectivity Measures
N/A N=39 VOCALE LBD+ for Caregivers of Persons With Lewy Body Dementia
Caregiver Burden · Lewy Body Disease · Stress
Primary: Effect Size of Change From Baseline Caregiving Mastery at 4 Weeks — -0.04 score on a scale
Phase 4 N=83 Lithium As a Treatment to Prevent Impairment of Cognition in Elders
Mild Cognitive Impairment
Primary: California Verbal Learning Test II — 6.9; 6.2; 6.46; 5.10 units on a scale — p=0.048
Phase 4 N=28 Mild Cognitive Impairment in Parkinson's Disease
Parkinson's Disease · Mild Cognitive Impairment
Primary: Alzheimer's Disease Cooperative Study- Clinical Global Impression Change (ADCS-CGIC) — 3.92; 3.48 scores on the CGIC